Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function

被引：0
|
作者：
Michelle Treitel
Thomas Marbury
Richard A. Preston
Ilias Triantafyllou
William Feely
Edward O’Mara
Claudia Kasserra
Samir Gupta
Eric A. Hughes
机构：
[1] Merck Sharp & Dohme Corp.,Division of Clinical Pharmacology Research Unit, Miller School of Medicine
[2] Orlando Clinical Research Center,Merck Research Laboratories
[3] University of Miami,undefined
[4] Merck & Co.,undefined
来源：
Clinical Pharmacokinetics | 2012年 / 51卷 / 9期
关键词：
Hepatic Impairment; Boceprevir; Severe Hepatic Impairment; Mild Hepatic Impairment; Median Tmax;
D O I：
10.1007/BF03261935
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 628
页数：9
相关论文
共 50 条
  • [31] Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency
    Lasseter, Kenneth C.
    Sologuren, Ander
    La Noce, Anna
    Dilzer, Stacy C.
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (09) : 665 - 673
  • [32] The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function
    Hruska, Matthew W.
    Adamczyk, Robert
    Colston, Elizabeth
    Hesney, Michael
    Stonier, Michele
    Myler, Heather
    Bertz, Richard
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (03) : 515 - 524
  • [33] Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients
    El-Assal, Mona I.
    Helmy, Sally A.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2014, 35 (07) : 405 - 416
  • [34] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Kurata, Akifumi
    Yoshida, Takafumi
    Inoue, Megumi
    Ishizuka, Tomoko
    Nakatsu, Takafumi
    Shimizu, Takako
    Kato, Manabu
    Nishikawa, Yasuhiro
    Ishizuka, Hitoshi
    [J]. ADVANCES IN THERAPY, 2020, 37 (01) : 253 - 264
  • [35] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
    Akifumi Kurata
    Takafumi Yoshida
    Megumi Inoue
    Tomoko Ishizuka
    Takafumi Nakatsu
    Takako Shimizu
    Manabu Kato
    Yasuhiro Nishikawa
    Hitoshi Ishizuka
    [J]. Advances in Therapy, 2020, 37 : 253 - 264
  • [36] Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
    Sidharta, Patricia N.
    Ulc, Ivan
    Dingemanse, Jasper
    [J]. CLINICAL DRUG INVESTIGATION, 2019, 39 (11) : 1117 - 1123
  • [37] PHARMACOKINETICS AND DOSE RECOMMENDATIONS OF FLEROXACIN IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
    HOFFLER, D
    PECH, M
    KOEPPE, P
    METZ, R
    SORGEL, F
    [J]. ACTA THERAPEUTICA, 1988, 14 (02) : 121 - 134
  • [38] Single-dose pharmacokinetics and tolerability of aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment
    Sidharta, P. N.
    Ulc, I.
    Dingemanse, J.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S92 - S92
  • [39] Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment
    Patricia N. Sidharta
    Ivan Ulč
    Jasper Dingemanse
    [J]. Clinical Drug Investigation, 2019, 39 : 1117 - 1123
  • [40] SINGLE DOSE PHARMACOKINETICS OF KETOROLAC IN HEALTHY-YOUNG AND RENAL IMPAIRED SUBJECTS
    MARTINEZ, JJ
    GARG, DC
    PAGES, LJ
    JALLAD, NS
    YEE, JP
    MROSZCACK, ES
    RENNEKE, GA
    WEIDLER, DJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (09): : 722 - 722
12345